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Abstract
Purpose
To evaluate the clinical benefit of eliminating BAK from prostaglandin analog therapy examining the safety and efficacy of
polyquad -preserved travoprost ophthalmic solution compared to previous use of latanoprost monotherapy.
Methods
This was an observational study. Consecutive adults with open-angle glaucoma or ocular hypertension treated with
latanoprost monotherapy who were going to change brand therapy to the generic one, were switched to travoprost
BAK-free ophthalmic solution. All patients were submitted to an ophthalmic examination, IOP measurement and ocular
surface status (BUT and corneal staining) evaluation. Patients' discomfort was evaluated with the Ocular Surface Disease
Index (OSDI). All examinations were performed at baseline and 6 months later. Descriptive statistics were produced for
demographic and clinical characteristics of cases. Median and interquartile range are presented for non-normally
distribuited variables. For group comparison, parametric and non-parametric tests were used for quantitative variables
and Pearson’s χ2 test for categorical variables. All analysis refer to right eye, left eye’s data are similar.
Results
44 patients were enrolled and treated with polyquad-preserved travoprost once a day. TF-BUT changed from 8 [IQR 6-10]
sec at baseline to 10 [IQR 8-12] sec at 6 month (p<0.0001). No eye developed corneal staining that statistically improved
after switching monotherapy: punctatae keratitis was absent in 13 (29.5%) patients at baseline and in 31 (70.4%) after 6
months. OSDI was (median [IQR]) 16 [10-30] at baseline and 9 [2-20] at 6 months (p=.18). The median [IQR] baseline IOP
was 18 [15.5-21] mmHg and 16 [14-17] mmHg (p<.0001) after 6 months. At baseline, 18 (40.9%) patients had an IOP
value < 18 mmHg, 11 (25%) < 16 mmHg, 2 (4.3%) < 14 mmHg and 1 (2.3%) < 12 mmHg, 6 months later the proportions
were as follows 36 (81.8%) (p<.0001), 21 (47.7%) (p=.0129), 8 (18.2%) (p=.0313) and 6 (13.6%) (p=.065), respectively.
Conclusions
No patient switched from BAK-preserved latanoprost to polyquad-preserved travoprost developed ocular surface disease
after 6 months. Ocular surface status statistically improved when examined by BUT and corneal staining. Many patients
reached a lower IOP. Polyquad-preserved travoprost is therefore an effective drug that is safe for the ocular surface
status.
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